{"id":831331,"date":"2025-03-30T17:03:04","date_gmt":"2025-03-30T21:03:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/"},"modified":"2025-03-30T17:03:04","modified_gmt":"2025-03-30T21:03:04","slug":"vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/","title":{"rendered":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN CARLOS, Calif., March  30, 2025  (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company\u2019s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20<sup>\u00ae<\/sup> in healthy infants.<\/p>\n<p>To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international) and refer to conference ID PCVX0331. A live webcast of the conference call will also be available on the investor relations page of the\u00a0Vaxcyte corporate website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yNWDcHkDXliKjyzG1daBQRcx84kfypam-WM__BUBbOtjFvnzBe4v1ClqY8_ggVJH16GWBMC7rDVHv-eGdQxytvpZB9I1pZQcXWOO9sCUW6xDAm5PRQhqhZRcpGa23PI8Pab0tiALRLiwqsjWM4lJluDZFZVwHbH17zf_VpgNKRwW7RhkeAazZp0fEcB1xs2dTKOFAxS4xmbjAuerme3dVJEDk3WF2_QAQuuXUpNLnXw=\" rel=\"nofollow\" target=\"_blank\">www.vaxcyte.com<\/a>. After the live webcast, the event will remain archived on the\u00a0Vaxcyte website for 30 days.<\/p>\n<p>\n        <strong>About Vaxcyte<\/strong><br \/>\n        <br \/>Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of IPD in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company\u2019s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.<\/p>\n<p>Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF\u2122 cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company\u2019s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte\u2019s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yNWDcHkDXliKjyzG1daBQXBITU-rpCiM6-wTJhh5kOLh9x07s9yukXzKasjImGOb8N1sp-cD6wFmPYUBqTs1SruN3QXSscCSmKSF8Fvc-Q7RK-CTnEqlx200jpc3nKKjEnBwTYDl3uNmmk3vN1jVA0YAUKUb8x4TOpS-xS4RoAYxxRQCVYdmrd2k7GPhQxh-yEQLaxXrc-LTiT3gc7hGNyRPl0BHty8wdmiCvMbnEmZIsIGE87q04GhvMYNNi1todcO0WH2iYK9yP3k9z2IuOXSg8BoK48sGHkR4PXDOK4HjLj9DtRh2aObuTr1PnMfj5A7l7FajZMKvq_0KPizyM_SSRi-pOlBlWCmNJkdV3LKhwUmgUPiDeBVegkaZ_Qlmd5zxAf7tFaIfy4QQdtYuKpr1DNBhlKeWXrKu2MVqdk1XyU-2HqTlBVW-fkg6U32Rok9OtSj2In6mUe5e7WvUd0-TI79ikpp5h_Xejv5w4aY1w0BK3vZFxPn2fCGSgeXVqX50t2_HYPw6eic5GnlpzhRuRyj7rBat__UkQljhIwgBnrOLRSNL03vZlEKVh9PG95u3GX5QkJjFzeDC84Wx3YJ4gtvVoSFNoHqWCBvxhYuW0DEcTv5-EV_dAJtRNobcKeCXGnq8RqcCMx52tvNTLjgyxzbRWFl4XtiQD_dkSIguhdQNhx5WzAqBVWc1iWQQ\" rel=\"nofollow\" target=\"_blank\">www.vaxcyte.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>Patrick Ryan, Executive Director, Corporate Affairs<br \/>Vaxcyte, Inc.<br \/>415-606-5135<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jaYVDJzVfKbNWMesFxJMqDU3zT1IURm71a6eDzk8jmkQlLkWXOiZHRlCggqNqNgJ1QXjHOkBrR_-tttKCHdUv-1dDjKKftLZfnU3ZOYM0HYKWM5T2L-AmlY-jSWkCinTsfwkeMNx28LJw797T3SOQ-8ByR2IvKvAdskShopKU42i_6zslnLMpufJCQtk0JRmcOx9aZ1NxalimW73hv1EC3dIae0dri_D1RHRowDCZRPN4AyzhQ03ubY5_kvhESMnGub79S1Bqi9lHWgAw0thtQ==\" rel=\"nofollow\" target=\"_blank\">media@vaxcyte.com<\/a><\/p>\n<p>Jennifer Zibuda, Senior Director, Investor Relations\u00a0<br \/>Vaxcyte, Inc.<br \/>860-729-8902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7X8q__p-A3g31Ij158WCstr6PKFFV3A07YqDSXmqeEeEnHNoBI3Z0iGWSIiwa_-5kXJixNTPDyM5Xwxz8RYIfkdNyoHmskP_WIRYT0yZHJ8u5HIB-4aNG2_T-g02KSexOucm9Cix4FmXCoaGxIkbnsuelCUHXRWuUqQuUOHbBTzvnvvMxheTBhCsOFuzj82reNE01_aFs6Sx1UXSf_VyBVDtMf4Vp1uGUXSx1roCmpFNE5CsSJ_w3beWzxpk4UTomTAFaqsQY4pRiQPsrqFI0A==\" rel=\"nofollow\" target=\"_blank\">investors@vaxcyte.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmVlYjIxN2YtOWVhNS00ZmI1LWJjMzktZGUzNTNkODQ0MThjLTEyMDczNzctMjAyNS0wMy0zMC1lbg==\/tiny\/Vaxcyte-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company\u2019s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20\u00ae in healthy infants. To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international) and refer to conference ID PCVX0331. A live webcast of the conference call will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-831331","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company\u2019s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20\u00ae in healthy infants. To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international) and refer to conference ID PCVX0331. A live webcast of the conference call will &hellip; Continue reading &quot;Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-30T21:03:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study\",\"datePublished\":\"2025-03-30T21:03:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/\"},\"wordCount\":482,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/\",\"name\":\"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ=\",\"datePublished\":\"2025-03-30T21:03:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/","og_locale":"en_US","og_type":"article","og_title":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - Market Newsdesk","og_description":"SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company\u2019s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20\u00ae in healthy infants. To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international) and refer to conference ID PCVX0331. A live webcast of the conference call will &hellip; Continue reading \"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-30T21:03:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study","datePublished":"2025-03-30T21:03:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/"},"wordCount":482,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/","name":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ=","datePublished":"2025-03-30T21:03:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzU0NiM2ODQxODA2IzIxOTU4MjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-vax-24-infant-phase-2-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=831331"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831331\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=831331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=831331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=831331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}